Epizyme (NASDAQ: EPZM) said Monday that a pediatric patient taking its experimental cancer drug tazemetostat developed a new cancer, different than the one tazemetostat had been treating. The secondary cancer, a lymphoma, spurred the Food and Drug Administration to halt all new enrollment in tazemetostat trials.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,